NDC 67296-0306 Lorazepam

NDC Product Code 67296-0306

NDC CODE: 67296-0306

Proprietary Name: Lorazepam What is the Proprietary Name?
The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.

Drug Use Information

Drug Use Information
The drug use information is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate. This information is not individual medical advice and does not substitute for the advice of a health care professional. Always ask a health care professional for complete information about this product and your specific health needs.

  • This medication is used to treat anxiety. Lorazepam belongs to a class of drugs known as benzodiazepines which act on the brain and nerves (central nervous system) to produce a calming effect. This drug works by enhancing the effects of a certain natural chemical in the body (GABA).

Product Characteristics

Color(s):
WHITE (C48325)
Shape: ROUND (C48348)
Size(s):
7 MM
Imprint(s):
241;1;WATSON
Score: 2

NDC Code Structure

  • 67296 - Redpharm Drug Inc.

NDC 67296-0306-1

Package Description: 10 TABLET in 1 BOTTLE

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

NDC Product Information

Lorazepam with NDC 67296-0306 is a product labeled by Redpharm Drug Inc.. The product's dosage form is and is administered via form. The RxNorm Crosswalk for this NDC code indicates a single RxCUI concept is associated to this product: 197901.

Inactive Ingredient(s)

About the Inactive Ingredient(s)
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product.

  • LACTOSE (UNII: J2B2A4N98G)
  • MAGNESIUM STEARATE (UNII: 70097M6I30)
  • CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)
  • POLACRILIN POTASSIUM (UNII: 0BZ5A00FQU)

Product Labeler Information

What is the Labeler Name?
Name of Company corresponding to the labeler code segment of the Product NDC.

Labeler Name: Redpharm Drug Inc.
Labeler Code: 67296
Start Marketing Date: 10-31-1991 What is the Start Marketing Date?
This is the date that the labeler indicates was the start of its marketing of the drug product.

Listing Expiration Date: 12-31-2017 What is the Listing Expiration Date?
This is the date when the listing record will expire if not updated or certified by the product labeler.

Exclude Flag: I - INACTIVATED, the listing data was inactivated by the FDA. What is the NDC Exclude Flag?
This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions ("Y"), or because the listing certification is expired ("E"), or because the listing data was inactivated by FDA ("I"). Values = "Y", "N", "E", or "I".

* Please review the disclaimer below.

Information for Patients

Lorazepam

Lorazepam is pronounced as (lor a' ze pam)

Why is lorazepam medication prescribed?
Lorazepam is used to relieve anxiety. Lorazepam is in a class of medications called benzodiazepines. It works by slowing activity in the brain to allow for relaxation....
[Read More]

* Please review the disclaimer below.

Lorazepam Product Labeling Information

The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.

Product Labeling Index

General

Acetaminophen and codeine phosphate tablets should be prescribed with caution in certain special-risk patients, such as the elderly or debilitated, and those with severe impairment of renal or hepatic function, head injuries, elevated intracranial pressure, acute abdominal conditions, hypothyroidism, urethral stricture, Addison's disease, or prostatic hypertrophy.

Ultra-Rapid Metabolizers Of Codeine

Some individuals may be ultra-rapid metabolizers due to a specific CYP2D6*2x2 genotype. These individuals convert codeine into its active metabolite, morphine, more rapidly and completely than other people. This rapid conversion results in higher than expected serum morphine levels. Even at labeled dosage regiments, individuals who are ultra-rapid metabolizers may experience overdose symptoms such as extreme sleepiness, confusion or shallow breathing.The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5 to 1% in Chinese and Japanese, 0.5 to 1% in Hispanics, 1 to 10% in Caucasians, 3% in African Americans, and 16 to 28% in North Africans, Ethiopians and Arabs. Data is not available for other ethnic groups.When physicians prescribe codeine-containing drugs, they should choose the lowest effective dose for the shortest period of time and should inform their patients about these risks and the signs of morphine overdose (see PRECAUTIONS, Nursing Mothers).

Information For Patients

Caution patients that some people have a variation in a liver enzyme and change codeine into morphine more rapidly and completely than other people. These people are ultra-rapid metabolizers and are more likely to have higher-than-normal levels of morphine in their blood after taking codeine which can result in overdose symptoms such as extreme sleepiness, confusion, or shallow breathing. In most cases, it is unknown if someone is an ultra-rapid codeine metabolizer.Nursing mothers taking codeine can also have higher morphine levels in their breast milk if they are ultra-rapid metabolizers. These higher levels of morphine in breast milk may lead to life-threatening or fatal side effects in nursing babies. Instruct nursing mothers to watch for signs of morphine toxicity in their infants including increased sleepiness (more than usual), difficulty breastfeeding, breathing difficulties, or limpness. Instruct nursing mothers to talk to the baby’s doctor immediately if they notice these signs and, if they cannot reach the doctor right away, to take the baby to an emergency room or call 911 (or local emergency services).Codeine may impair mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. Such tasks should be avoided while taking this product.Alcohol and other CNS depressants may produce an additive CNS depression, when taken with this combination product, and should be avoided.Codeine may be habit-forming. Patients should take the drug only for as long as it is prescribed, in the amounts prescribed, and no more frequently than prescribed.

To assure the safe and effective use of lorazepam, patients should be informed
that, since benzodiazepines may produce psychological and physical dependence,
it is advisable that they consult with their physician before either increasing
the dose or abruptly discontinuing this drug.

Laboratory Tests

In patients with severe hepatic or renal disease, effects of therapy should be monitored with serial liver and/or renal function tests.

Drug Interactions

This drug may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.

Drug/Laboratory Test Interactions

Codeine may increase serum amylase levels.Acetaminophen may produce false-positive test results for urinary 5-hydroxyindoleacetic acid.

Carcinogenesis, Mutagenesis, Impairment Of Fertility

No adequate studies have been conducted in animals to determine whether acetaminophen and codeine have a potential for carcinogenesis or mutagenesis. No adequate studies have been conducted in animals to determine whether acetaminophen has a potential for impairment of fertility.Acetaminophen and codeine have been found to have no mutagenic potential using the Ames Salmonella-Microsomal Activation test, the Basc test on Drosophila germ cells, and the Micronucleus test on mouse bone marrow.

Codeine

A study in rats and rabbits reported no teratogenic effect of codeine administered during the period of organogenesis in doses ranging from 5 to 120 mg/kg. In the rat, doses at the 120 mg/kg level, in the toxic range for the adult animal, were associated with an increase in embryo resorption at the time of implantation. In another study a single 100 mg/kg dose of codeine administered to pregnant mice reportedly resulted in delayed ossification in the offspring.There are no adequate and well-controlled studies in pregnant women. Acetaminophen and codeine phosphate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nonteratogenic Effects

Dependence has been reported in newborns whose mothers took opiates regularly during pregnancy. Withdrawal signs include irritability, excessive crying, tremors, hyperreflexia, fever, vomiting, and diarrhea. These signs usually appear during the first few days of life.

Labor And Delivery

Narcotic analgesics cross the placental barrier. The closer to delivery and the larger the dose used, the greater the possibility of respiratory depression in the newborn. Narcotic analgesics should be avoided during labor if delivery of a premature infant is anticipated. If the mother has received narcotic analgesics during labor, newborn infants should be observed closely for signs of respiratory depression. Resuscitation may be required (see OVERDOSAGE). The effect of codeine, if any, on the later growth, development, and functional maturation of the child is unknown.

Nursing Mothers

Acetaminophen is excreted in breast milk in small amounts, but the significance of its effects on nursing infants is not known. Because of the potential for serious adverse reactions in nursing infants from acetaminophen, a decision should be made whether to discontinue the drug, taking into account the importance of the drug to the mother.Codeine is secreted into human milk. In women with normal codeine metabolism (normal CYP2D6 activity), the amount of codeine secreted into human milk is low and dose-dependent. Despite the common use of codeine products to manage postpartum pain, reports of adverse events in infants are rare. However, some women are ultra-rapid metabolizers of codeine. These women achieve higher-than-expected serum levels of codeine’s active metabolite, morphine, leading to higher-than-expected levels of morphine in breast milk and potentially dangerously high serum morphine levels in their breastfed infants. Therefore, maternal use of codeine can potentially lead to serious adverse reactions, including death, in nursing infants.The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5 to 1% in Chinese and Japanese, 0.5 to 1% in Hispanics, 1 to 10% in Caucasians, 3% in African Americans, and 16 to 28% in North Africans, Ethiopians and Arabs. Data is not available for other ethnic groups.The risk of infant exposure to codeine and morphine through breast milk should be weighed against the benefits of breastfeeding for both the mother and baby. Caution should be exercised when codeine is administered to a nursing woman. If a codeine containing product is selected, the lowest dose should be prescribed for the shortest period of time to achieve the desired clinical effect. Mothers using codeine should be informed about when to seek immediate medical care and how to identify the signs and symptoms of neonatal toxicity, such as drowsiness or sedation, difficulty breastfeeding, breathing difficulties, and decreased tone, in their baby. Nursing mothers who are ultra-rapid metabolizers may also experience overdose symptoms such as extreme sleepiness, confusion or shallow breathing. Prescribers should closely monitor mother-infant pairs and notify treating pediatricians about the use of codeine during breastfeeding (see PRECAUTIONS, General, Ultra-Rapid Metabolizers of Codeine).

Lorazepam has been detected in human breast milk; therefore, it
should not be administered to breast-feeding women, unless the expected benefit
to the woman outweighs the potential risk to the infant.Sedation and inability to suckle have occurred in neonates of lactating
mothers taking benzodiazepines. Infants of lactating mothers should be observed
for pharmacological effects (including sedation and irritability).

Controlled Substance

Acetaminophen and codeine phosphate tablets are classified as a Schedule III controlled substance.

Abuse And Dependence

Codeine can produce drug dependence of the morphine type and, therefore, has the potential for being abused. Psychological dependence, physical dependence, and tolerance may develop upon repeated administration and it should be prescribed and administered with the same degree of caution appropriate to the use of other oral narcotic medications.

Description

Lorazepam, an antianxiety agent, has the chemical formula, 7-chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one:It is a nearly white powder almost insoluble in water. Each lorazepam tablet, to
be taken orally, contains 0.5 mg, 1 mg or 2 mg of lorazepam. The inactive
ingredients present are lactose, magnesium stearate, microcrystalline cellulose
and polacrilin potassium.

Clinical Pharmacology

Studies in healthy volunteers show that in single high doses
lorazepam has a tranquilizing action on the central nervous system with no
appreciable effect on the respiratory or cardiovascular systems.Lorazepam is readily absorbed with an absolute bioavailability of 90 percent.
Peak concentrations in plasma occur approximately 2 hours following
administration. The peak plasma level of lorazepam from a 2 mg dose is
approximately 20 ng/mL.The mean half-life of unconjugated lorazepam in human plasma is about 12
hours and for its major metabolite, lorazepam glucuronide, about 18 hours. At
clinically relevant concentrations, lorazepam is approximately 85% bound to
plasma proteins. Lorazepam is rapidly conjugated at its 3-hydroxy group into
lorazepam glucuronide which is then excreted in the urine. Lorazepam glucuronide
has no demonstrable CNS activity in animals.The plasma levels of lorazepam are proportional to the dose given. There is
no evidence of accumulation of lorazepam on administration up to six months.Studies comparing young and elderly subjects have shown that advancing age
does not have a significant effect on the pharmacokinetics of lorazepam.
However, in one study involving single intravenous doses of 1.5 to 3 mg of
lorazepam injection, mean total body clearance of lorazepam decreased by 20% in
15 elderly subjects of 60 to 84 years of age compared to that in 15 younger
subjects of 19 to 38 years of age.

Indications And Usage

Lorazepam is indicated for the management of anxiety disorders or
for the short-term relief of the symptoms of anxiety or anxiety associated with
depressive symptoms. Anxiety or tension associated with the stress of everyday
life usually does not require treatment with an anxiolytic.The effectiveness of lorazepam in long-term use, that is, more than 4 months,
has not been assessed by systematic clinical studies. The physician should
periodically reassess the usefulness of the drug for the individual patient.

Contraindications

Lorazepam is contraindicated in patients with- hypersensitivity to
benzodiazepines or to any components of the formulation.- acute narrow-angle
glaucoma.

Warnings

Pre-existing depression may emerge or worsen during use of
benzodiazepines including lorazepam. Lorazepam is not recommended for use in
patients with a primary depressive disorder or psychosis.Use of benzodiazepines, including lorazepam, both used alone and in
combination with other CNS depressants, may lead to potentially fatal
respiratory depression. (See PRECAUTIONS, Clinically
Significant Drug Interactions)Use of benzodiazepines, including lorazepam, may lead to physical and
psychological dependence.As with all patients on CNS-depressant drugs, patients receiving lorazepam
should be warned not to operate dangerous machinery or motor vehicles and that
their tolerance for alcohol and other CNS depressants will be diminished.

Physical And Psychological Dependence

The use of benzodiazepines, including lorazepam, may lead to physical and
psychological dependence. The risk of dependence increases with higher doses and
longer term use and is further increased in patients with a history of
alcoholism or drug abuse or in patients with significant personality disorders.
The dependence potential is reduced when lorazepam is used at the appropriate
dose for short-term treatment. Addiction-prone individuals (such as drug addicts
or alcoholics) should be under careful surveillance when receiving lorazepam or
other psychotropic agents.In general, benzodiazepines should be prescribed for short periods only (e.g.
2- 4 weeks). Extension of the treatment period should not take place without
reevaluation of the need for continued therapy. Continuous long-term use of
product is not recommended. Withdrawal symptoms (e.g. rebound insomnia) can
appear following cessation of recommended doses after as little as one week of
therapy. Abrupt discontinuation of product should be avoided and a gradual
dosage-tapering schedule followed after extended therapy.Abrupt termination of treatment may be accompanied by withdrawal symptoms.
Symptoms reported following discontinuation of benzodiazepines include headache,
anxiety, tension, depression, insomnia, restlessness, confusion, irritability,
sweating, rebound phenomena, dysphoria, dizziness, derealization,
depersonalization, hyperacusis, numbness/tingling of extremities,
hypersensitivity to light, noise, and physical contact/perceptual changes,
involuntary movements, nausea, vomiting, diarrhea, loss of appetite,
hallucinations/delirium, convulsions/seizures, tremor, abdominal cramps,
myalgia, agitation, palpitations, tachycardia, panic attacks, vertigo,
hyperreflexia, short-term memory loss, and hyperthermia. Convulsions/seizures
may be more common in patients with pre-existing seizure disorders or who are
taking other drugs that lower the convulsive threshold such as
antidepressants.There is evidence that tolerance develops to the sedative effects of
benzodiazepines.Lorazepam may have abuse potential, especially in patients with a history of
drug and/or alcohol abuse.

Precautions

In patients with depression, a possibility for suicide should be
borne in mind; benzodiazepines should not be used in such patients without
adequate anti-depressant therapy.Lorazepam should be used with caution in patients with compromised
respiratory function (e.g. COPD, sleep apnea syndrome).Elderly or debilitated patients may be more susceptible to the sedative
effects of lorazepam. Therefore, these patients should be monitored frequently
and have their dosage adjusted carefully according to patient response; the
initial dosage should not exceed 2 mg.Paradoxical reactions have been occasionally reported during benzodiazepine
use. Such reactions may be more likely to occur in children and the elderly.
Should these occur, use of the drug should be discontinued.The usual precautions for treating patients with impaired renal and hepatic
function should be observed. As with all benzodiazepines, the use of lorazepam
may worsen hepatic encephalopathy; therefore, lorazepam should be used with
caution in patients with severe hepatic insufficiency and/or encephalopathy.
Dosage for patients with severe hepatic insufficiency should be adjusted
carefully according to patient response; lower doses may be sufficient in such
patients.In patients where gastrointestinal or cardiovascular disorders coexist with
anxiety, it should be noted that lorazepam has not been shown to be of
significant benefit in treating the gastrointestinal or cardiovascular
component.Esophageal dilation occurred in rats treated with lorazepam for more than one
year at 6 mg/kg/day. The no-effect dose was 1.25 mg/kg/day (approximately 6
times the maximum human therapeutic dose of 10 mg per day). The effect was
reversible only when the treatment was withdrawn within two months of first
observation of the phenomenon. The clinical significance of this is unknown.
However, use of lorazepam for prolonged periods and in geriatric patients
requires caution, and there should be frequent monitoring for symptoms of upper
G.I. disease.Safety and effectiveness of lorazepam in children of less than 12 years have
not been established.

Essential Laboratory Tests

Some patients on lorazepam have developed leukopenia, and some have had
elevations of LDH. As with other benzodiazepines, periodic blood counts and
liver-function tests are recommended for patients on long-term therapy.

Clinically Significant Drug Interactions

The benzodiazepines, including lorazepam, produce increased
CNS-depressant effects when administered with other CNS depressants such as
alcohol, barbiturates, antipsychotics, sedative/hypnotics, anxiolytics,
antidepressants, narcotic analgesics, sedative antihistamines, anticonvulsants,
and anesthetics.Concomitant use of clozapine and lorazepam may produce marked sedation,
excessive salivation, hypotension, ataxia, delirium, and respiratory arrest.Concurrent administration of lorazepam with valproate results in increased
plasma concentrations and reduced clearance of lorazepam. Lorazepam dosage
should be reduced to approximately 50% when coadministered with valproate.Concurrent administration of lorazepam with probenecid may result in a more
rapid onset or prolonged effect of lorazepam due to increased half-life and
decreased total clearance. Lorazepam dosage needs to be reduced by approximately
50% when coadministered with probenecid.The effects of probenecid and valproate on lorazepam may be due to inhibition
of glucuronidation.Administration of theophylline or aminophylline may reduce the sedative
effects of benzodiazepines, including lorazepam.

Carcinogenesis And Mutagenesis

No evidence of carcinogenic potential emerged in rats during an 18-month study
with lorazepam. No studies regarding mutagenesis have been performed.

Pregnancy

Reproductive studies in animals were performed in mice, rats, and
two strains of rabbits. Occasional anomalies (reduction of tarsals, tibia,
metatarsals, malrotated limbs, gastroschisis, malformed skull, and
microphthalmia) were seen in drug-treated rabbits without relationship to
dosage. Although all of these anomalies were not present in the concurrent
control group, they have been reported to occur randomly in historical controls.
At doses of 40 mg/kg and higher, there was evidence of fetal resorption and
increased fetal loss in rabbits which was not seen at lower doses.The clinical significance of the above findings is not known. However, an
increased risk of congenital malformations associated with the use of minor
tranquilizers (chlordiazepoxide, diazepam, and meprobamate) during the first
trimester of pregnancy has been suggested in several studies. Because the use of
these drugs is rarely a matter of urgency, the use of lorazepam during this
period should be avoided. The possibility that a woman of childbearing potential
may be pregnant at the time of institution of therapy should be considered.
Patients should be advised that if they become pregnant, they should communicate
with their physician about the desirability of discontinuing the drug.In humans, blood levels obtained from umbilical cord blood indicate placental
transfer of lorazepam and lorazepam glucuronide. Infants of mothers who ingested
benzodiazepines for several weeks or more preceding delivery have been reported
to have withdrawal symptoms during the postnatal period. Symptoms such as
hypoactivity, hypotonia, hypothermia, respiratory depression, apnea, feeding
problems, and impaired metabolic response to cold stress have been reported in
neonates born of mothers who have received benzodiazepines during the late phase
of pregnancy or at delivery.

Geriatric Use

Clinical studies of lorazepam generally were not adequate to
determine whether subjects aged 65 and over respond differently than younger
subjects; however, the incidence of sedation and unsteadiness was observed to
increase with age (see ADVERSE
REACTIONS).Age does not appear to have a significant effect on lorazepam kinetics (see
CLINICAL
PHARMACOLOGY).Clinical circumstances, some of which may be more common in the elderly, such
as hepatic or renal impairment, should be considered. Greater sensitivity (e.g.,
sedation) of some older individuals cannot be ruled out. In general, dose
selection for an elderly patient should be cautious, and lower doses may be
sufficient in these patients (see DOSAGE AND
ADMINISTRATION).

Adverse Reactions

Most adverse reactions to benzodiazepines, including CNS effects
and respiratory depression, are dose dependent, with more severe effects
occurring with high doses.In a sample of about 3500 patients treated for anxiety, the most frequent
adverse reaction to lorazepam was sedation (15.9%), followed by dizziness
(6.9%), weakness (4.2%), and unsteadiness (3.4%). The incidence of sedation and
unsteadiness increased with age.Other adverse reactions to benzodiazepines, including lorazepam are fatigue,
drowsiness, amnesia, memory impairment, confusion, disorientation, depression,
unmasking of depression, disinhibition, euphoria, suicidal ideation/attempt,
ataxia, asthenia, extrapyramidal symptoms, convulsions/seizures tremor, vertigo,
eye-function/visual disturbance (including diplopia and blurred vision),
dysarthria/slurred speech, change in libido, impotence, decreased orgasm;
headache, coma; respiratory depression, apnea, worsening of sleep apnea,
worsening of obstructive pulmonary disease; gastrointestinal symptoms including
nausea, change in appetite, constipation, jaundice, increase in bilirubin,
increase in liver transaminases, increase in alkaline phosphatase;
hypersensitivity reactions, anaphylactic/oid reactions; dermatological symptoms,
allergic skin reactions, alopecia; S IADH, hyponatremia; thrombocytopenia,
agranulocytosis, pancytopenia; hypothermia; and autonomic manifestations.Paradoxical reactions, including anxiety, excitation, agitation, hostility,
aggression, rage, sleep disturbances/insomnia, sexual arousal, and
hallucinations may occur. Small decreases in blood pressure and hypotension may
occur but are usually not clinically significant, probably being related to the
relief of anxiety produced by lorazepam.

Overdosage

In postmarketing experience, overdose with lorazepam has occurred predominantly
in combination with alcohol and/or other drugs. Therefore, in the management of
overdosage, it should be borne in mind that multiple agents may have been taken.SymptomsOverdosage of benzodiazepines is usually manifested by varying degrees of
central nervous system depression ranging from drowsiness to coma. In mild
cases, symptoms include drowsiness, mental confusion, paradoxical reactions,
dysarthria and lethargy. In more serious cases, and especially when other drugs
or alcohol were ingested, symptoms may include ataxia, hypotonia, hypotension,
cardiovascular depression, respiratory depression, hypnotic state, coma, and
death.MANAGEMENTGeneral supportive and symptomatic measures are recommended; vital signs must
be monitored and the patient closely observed. When there is a risk of
aspiration, induction of emesis is not recommended. Gastric lavage may be
indicated if performed soon after ingestion or in symptomatic patients.
Administration of activated charcoal may also limit drug absorption.
Hypotension, though unlikely, usually may be controlled with norepinephrine
bitartrate injection. Lorazepam is poorly dialyzable. Lorazepam glucuronide, the
inactive metabolite, may be highly dialyzable.The benzodiazepine antagonist flumazenil may be used in hospitalized patients
as an adjunct to, not as a substitute for, proper management of benzodiazepine
overdose. The prescriber should be aware of a risk of seizure
in association with flumazenil treatment, particularly in long-term
benzodiazepine users and in cyclic antidepressant overdose. The complete
flumazenil package insert including CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS should
be consulted prior to use.

Dosage And Administration

Lorazepam is administered orally. For optimal results, dose,
frequency of administration, and duration of therapy should be individualized
according to patient response. To facilitate this, 0.5 mg, 1 mg, and 2 mg
tablets are available.The usual range is 2 to 6 mg/day given in divided doses, the largest dose
being taken before bedtime, but the daily dosage may vary from 1 to 10
mg/day.For anxiety, most patients require an initial dose of 2 to 3 mg/day given
b.i.d. or t.i.d.For insomnia due to anxiety or transient situational stress, a single daily
dose of 2 to 4 mg may be given, usually at bedtime.For elderly or debilitated patients, an initial dosage of 1 to 2 mg/day in
divided doses is recommended, to be adjusted as needed and tolerated.The dosage of lorazepam should be increased gradually when needed to help
avoid adverse effects. When higher dosage is indicated, the evening dose should
be increased before the daytime doses.

How Supplied

Lorazepam Tablets USP are available in the following dosage
strengths:0.5 mg: white, scored, round flat faced beveled edge, debossed with 240 over 0.5 on one side and WATSON on the other side, supplied in bottles of 100, 500 and
1000.1 mg: white, scored, round flat faced beveled edge, debossed with 241 over 1 on one side and WATSON on the other side, supplied in bottles of 100, 500 and
1000.2 mg: white, scored, round flat faced beveled edge, debossed with 242 over 2 on one side and WATSON on the other side, supplied in bottles of 100, 500 and
1000.Store at 20°-25°C (68°-77°F). [See USP controlled room
temperature.]Dispense in a tight, light-resistant container as defined in
the USP.Manufactured by:Watson Laboratories, Inc.Corona, CA 92880 USARevised: June 20080608B173019

Package Label

Copy of label

* Please review the disclaimer below.